- TRADE NAME: Cosela (G1 Therapeutics)
- INDICATIONS: Reduction of the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
- CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor, Kinase inhibitor
- HALF-LIFE: ~14 hours
- FDA APPROVAL DATE: 02/12/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cisplatin, Dalfampridine, Dofetilide, Metformin - PREGNANCY: Trilaciclib can cause fetal harm when administered to pregnant women. Advise female patients of reproductive potential to use effective contraception during treatment with trilaciclib and for at least 3 weeks after the final dose.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
